144,342 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Walleye Capital LLC

Market Beat
2025.04.18 09:18
portai
I'm PortAI, I can summarize articles.

Walleye Capital LLC acquired 144,342 shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) during the fourth quarter, valued at approximately $8.08 million, according to a recent SEC filing. Other institutional investors also increased their stakes in the company. Rhythm Pharmaceuticals' stock opened at $62.09, with a market cap of $3.93 billion. The company reported a quarterly loss of $0.72 per share, missing estimates, but had revenue of $41.83 million. Analysts maintain a "buy" rating with a consensus price target of $74.92.

Walleye Capital LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 144,342 shares of the company's stock, valued at approximately $8,080,000. Walleye Capital LLC owned 0.23% of Rhythm Pharmaceuticals at the end of the most recent reporting period.

Get Rhythm Pharmaceuticals alerts:

  • 7 Stocks That Will Drive the Weight Loss Drugs Market

Several other institutional investors have also modified their holdings of the stock. SRS Capital Advisors Inc. grew its holdings in Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock valued at $25,000 after purchasing an additional 400 shares during the last quarter. Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at approximately $28,000. SBI Securities Co. Ltd. purchased a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter worth approximately $37,000. R Squared Ltd bought a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth approximately $44,000. Finally, KBC Group NV boosted its holdings in Rhythm Pharmaceuticals by 78.2% during the 4th quarter. KBC Group NV now owns 2,251 shares of the company's stock valued at $126,000 after acquiring an additional 988 shares during the period.

Rhythm Pharmaceuticals Stock Up 3.2 %

Rhythm Pharmaceuticals stock opened at $62.09 on Wednesday. The firm has a market cap of $3.93 billion, a P/E ratio of -14.34 and a beta of 2.32. The business has a fifty day moving average of $54.55 and a two-hundred day moving average of $55.43. Rhythm Pharmaceuticals, Inc. has a twelve month low of $35.17 and a twelve month high of $68.58.

  • 2 biotechs with promising weight-loss drugs coming

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The company had revenue of $41.83 million for the quarter, compared to analysts' expectations of $38.48 million. Equities analysts expect that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They set a "buy" rating and a $78.00 target price for the company. Wells Fargo & Company lifted their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the company an "overweight" rating in a report on Monday, April 7th. Jefferies Financial Group began coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They issued a "buy" rating and a $80.00 price objective for the company. JMP Securities reaffirmed a "market outperform" rating and set a $75.00 target price on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 price target (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. Thirteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $74.92.

Read Our Latest Stock Analysis on Rhythm Pharmaceuticals

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the sale, the executive vice president now owns 40,370 shares of the company's stock, valued at $2,078,247.60. This represents a 65.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Hunter C. Smith sold 1,678 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total transaction of $99,723.54. Following the completion of the transaction, the chief financial officer now directly owns 101,186 shares in the company, valued at $6,013,483.98. This represents a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 146,641 shares of company stock valued at $8,112,177. 5.60% of the stock is currently owned by insiders.

About Rhythm Pharmaceuticals

(Free Report)

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.

Featured Articles

  • Five stocks we like better than Rhythm Pharmaceuticals
  • The Most Important Warren Buffett Stock for Investors: His Own
  • Beware of BigBear.ai: Insiders Are Selling—Should You?
  • The Significance of Brokerage Rankings in Stock Selection
  • CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
  • Stock Dividend Cuts Happen Are You Ready?
  • Congress! Who Traded What During the Tariff-Induced Meltdown

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?

Before you consider Rhythm Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.

While Rhythm Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.